Other ROS generating therapeutic agents, including arsenic trioxide, 4-hydroxyphenyl-retinamide (4-HPR), have also been shown to augment the therapeutic effect of MDA-7/IL-24 in cancers of the pancreas and kidney [136,137]. Here, IL24 is linked to cancer.